ALE.P02

Alentis Therapeutics AG · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	ALE.P02
Sponsor	Alentis Therapeutics AG
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ALE.P02 CI brief — competitive landscape report
ALE.P02 updates RSS · CI watch RSS
Alentis Therapeutics AG portfolio CI